Tumor necrosis factor-α inhibitor-associated psoriasis: Facts and hypotheses
Int J Rheum Dis
.
2023 Jun;26(6):1011-1014.
doi: 10.1111/1756-185X.14661.
Authors
Feng Luo
1
2
,
Yung-Heng Lee
3
4
5
6
,
Wu-Kai Ma
1
2
,
Su-Boon Yong
7
8
,
Xue-Ming Yao
1
2
,
James Cheng-Chung Wei
7
9
10
Affiliations
1
Guizhou University of Traditional Chinese Medicine, Guiyang, China.
2
Department of Rheumatology and Immunology, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.
3
Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
4
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan.
5
Department of Senior Services Industry Management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
6
Department of Recreation and Sport Management, Shu-Te University, Kaohsiung, Taiwan.
7
Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
8
Division of Pediatric Allergy, Immunology, and Rheumatology, Lin-Shin Hospital, Taichung, Taiwan.
9
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
10
Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
PMID:
37306678
DOI:
10.1111/1756-185X.14661
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Psoriasis* / chemically induced
Tumor Necrosis Factor Inhibitors* / adverse effects
Substances
Tumor Necrosis Factor Inhibitors
Grants and funding
QiankehePlatformTalent[2020]2202/Guizhou Science and Technology Program Project
QiankeheSupport[2021]General006/Guizhou Science and Technology Program Project
QZYY-2020-021/Guizhou Provincial Administration of Traditional Chinese Medicine Project